What is nivolumab (an anti-PD-1 drug)?
Nivolumab is a cancer immunotherapy antibody that blocks the PD-1 (programmed death-1) receptor on immune cells. By blocking PD-1, it helps T cells recognize and attack cancer cells more effectively.
What cancers is nivolumab used for?
Nivolumab is used for several types of cancer across different settings (for example, advanced disease and some adjuvant or post-treatment situations, depending on indication and country). Common areas of use include lung cancer and cancers that may have specific biomarkers (such as mismatch repair deficiency), plus other solid tumors and some hematologic contexts. [1][2]
How does anti–PD-1 therapy work?
PD-1 is a checkpoint that can dampen T-cell activity. When tumors exploit this pathway, immune responses can weaken. Anti–PD-1 drugs like nivolumab block that checkpoint signaling, which can restore or enhance anti-tumor immune activity. [1]
What side effects do patients ask about with nivolumab?
Because nivolumab activates the immune system, it can cause immune-related side effects (sometimes affecting organs like the skin, gut, lungs, liver, endocrine glands, or other systems). These effects can range from mild to serious and usually require monitoring and, when needed, treatment interruption and immunosuppressive therapy. [1]
How is nivolumab given?
Nivolumab is typically administered by intravenous infusion in a clinical setting on a scheduled dosing interval, depending on the treatment plan and the specific indication. [1]
Nivolumab vs pembrolizumab: what’s the difference?
Nivolumab and pembrolizumab are both anti–PD-1 therapies, but they are different drugs with distinct dosing schedules and approved indications that can vary by region and treatment line. Choice depends on the cancer type, prior therapy, tumor markers, and local approval. [1][2]
What tests or biomarkers matter before or during treatment?
In many indications, clinicians consider tumor characteristics (including, for some cancers, biomarkers used to guide checkpoint inhibitor use), along with patient health status and baseline lab values. These decisions affect likelihood of benefit and risk management. [1][2]
Where can you find official details?
For the most accurate information on dosing, approved indications, and warnings, clinicians and patients typically rely on the local product label and regulatory guidance. [1][2]
Sources
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo
[2] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554